Form 4: RA Capital Increases Stake in Climb Bio via Warrants

RA Capital Management acquired 2,106,000 pre-funded warrants in Climb Bio, Inc. to increase its beneficial ownership position.

Summary

• RA Capital Management, L.P. and affiliated entities acquired 2,106,000 pre-funded warrants of Climb Bio, Inc. (CLYM).
• The warrants have an exercise price of $0.0001 per share.
• The transaction occurred on April 29, 2026.
• Following this transaction, the reporting persons beneficially own 22,546,000 shares of common stock.
• The warrants are exercisable immediately and have no expiration date, subject to a 33.0% beneficial ownership cap.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive event, as it reflects institutional confidence in the company's long-term prospects, though it introduces potential dilution.

Positives

• Demonstrates strong continued commitment and confidence from a major institutional investor.
• The acquisition of pre-funded warrants provides the company with immediate capital infusion.
• The reporting entities maintain a significant long-term stake in the issuer.

Negatives

• The transaction increases the potential for future dilution of existing shareholders upon warrant exercise.
• The concentration of ownership by RA Capital may limit the influence of other minority shareholders.

Risks

• The exercise of warrants is subject to a 33.0% ownership cap, which may restrict the timing of liquidity events for the investor.
• Market volatility could impact the value of the underlying common stock.
• Regulatory or legal changes affecting beneficial ownership reporting could impact future filings.

Future Outlook

The filing does not provide specific forward-looking guidance regarding company operations, focusing instead on the reporting of beneficial ownership changes.

Management Comments

• The reporting persons disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.

Industry Context

StockSavvy.ai notes that institutional investors like RA Capital frequently utilize pre-funded warrants in biotech to maintain or increase their equity stakes while managing regulatory ownership thresholds.

Comparison to Industry Standards

• The use of pre-funded warrants is a standard mechanism in the biotechnology sector for capital raises and maintaining ownership percentages.
• The 33% ownership cap is a common protective provision in institutional investment agreements to avoid triggering specific regulatory or tax implications.

Related Party Transactions

• The reporting persons are affiliated with the issuer through board representation (Dr. Andrew Levin).

Stakeholder Impact

• Shareholders may experience dilution if the warrants are exercised.
• The company gains additional capital to support its operations or research and development.

Next Steps

• Potential future exercise of the pre-funded warrants into common stock.
• Ongoing monitoring of beneficial ownership levels by the reporting persons.

Key Dates

Keywords

Climb Bio, CLYM, RA Capital Management, Form 4, Pre-funded warrants, Insider ownership, Biotech investment